EICHORCondition: Refractory Solid Tumor · Sponsor: The First Affiliated Hospital of Xiamen University
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This is an open-label, non-controlled, non-randomized study to assess the therapeutic efficacy of 177Lu-AB-3PRGD2 in patients with various solid tumors who will undergo radioligand therapy using 177Lu-AB-3PRGD.
This description comes directly from the study's public registry record.
Haojun Chen, MD, PhD · +8618659285282 · leochen0821@foxmail.com
Hao Fu · +8615959230059 · fuhaonuclear@163.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Xiamen University | Xiamen, Fujian, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06375564